This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Salmenkivi, K. Articles by Liu, J. Search for Related Content PubMed PubMed Citation Articles by Salmenkivi, K. Articles by Liu, J.

Inhibin/Activin ßB-Subunit Expression in Pheochromocytomas Favors Benign Diagnosis¹

Department of Pathology, Haartman Institute, University of Helsinki (K.S., J.A., R.V., A.I.K., P.H., J.L.), and HUCH Laboratory Diagnostics (K.S., J.A., R.V., A.I.K., P.H., J.L.) and Departments of Internal Medicine (V.I.) and Surgery (C.H.), Helsinki University Central Hospital, FIN-00014 Helsinki; and Department of Pediatrics, Kuopio University Hospital (R.V., J.L.), FIN-70211 Kuopio, Finland

Address all correspondence and requests for reprints to: Dr. Kaisa Salmenkivi, Haartman Institute, Department of Pathology, P.O. Box 21, University of Helsinki, FIN-00014 Helsinki, Finland. E-mail address: kaisa.salmenkivi{at}helsinki.fi

Malignancy of pheochromocytomas is difficult to estimate on the basis of histopathological features. Good prognostic markers are not available. In our search for new markers to differentiate malignant pheochromocytomas from benign ones we tested the value of inhibin/activin subunit expression. Inhibins are heterodimeric glycoproteins consisting of an -subunit and either a ßA- or a ßB-subunit. Activins are composed of ß-subunits only.

Immunohistochemically inhibin/activin ßB-subunit was strongly positive in the normal adrenal medulla, but the cortex was negative. A striking difference was found in inhibin/activin ßB expression between benign and malignant pheochromocytomas. The majority of benign adrenal tumors (27 of 30) showed strong or moderate immunoreactivity, whereas all seven malignant tumors were negative or only weakly positive for inhibin/activin ßB-subunit. The percentage of positively staining cells varied greatly in extraadrenal pheochromocytomas and in those benign tumors that showed over 5 mitoses/10 high power fields, necrosis, or capsular or vascular invasion, here called borderline tumors. Inhibin/activin ßB messenger ribonucleic acid was also found in pheochromocytomas. However, no significant differences in messenger ribonucleic acid levels were found in various types of tumors. Weak immunohistochemical positivity for inhibin/activin ßA-subunit was detected in the adrenal cortex, but the medulla and most of the pheochromocytomas were negative.

Our data show that inhibin/activin ßB-subunit is expressed in normal adrenal medullary cells. Strong staining is found in most benign adrenal pheochromocytomas, whereas malignant tumors are almost negative. This suggests that loss of inhibin/activin ßB-subunit expression in pheochromocytomas may be used as an indicator of malignant potential.

This article has been cited by other articles:

				A. Karagiannis, D. P Mikhailidis, V. G Athyros, and F. Harsoulis Pheochromocytoma: an update on genetics and management Endocr. Relat. Cancer, December 1, 2007; 14(4): 935 - 956. [Abstract] [Full Text] [PDF]

				A. Chrisoulidou, G. Kaltsas, I. Ilias, and A. B Grossman The diagnosis and management of malignant phaeochromocytoma and paraganglioma Endocr. Relat. Cancer, September 1, 2007; 14(3): 569 - 585. [Abstract] [Full Text] [PDF]

				G. A. Kaltsas, G. M. Besser, and A. B. Grossman The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors Endocr. Rev., June 1, 2004; 25(3): 458 - 511. [Abstract] [Full Text] [PDF]

				G. Mansmann, J. Lau, E. Balk, M. Rothberg, Y. Miyachi, and S. R. Bornstein The Clinically Inapparent Adrenal Mass: Update in Diagnosis and Management Endocr. Rev., April 1, 2004; 25(2): 309 - 340. [Abstract] [Full Text] [PDF]

				S. La Rosa, S. Uccella, S. Marchet, C. Capella, and R. V. Lloyd Localization of Inhibins and Activins in Normal Endocrine Cells and Endocrine Tumors of the Gut and Pancreas: an Immunohistochemical and In Situ Hybridization Study J. Histochem. Cytochem., February 1, 2004; 52(2): 217 - 225. [Abstract] [Full Text] [PDF]

				E. L. Bravo and R. Tagle Pheochromocytoma: State-of-the-Art and Future Prospects Endocr. Rev., August 1, 2003; 24(4): 539 - 553. [Abstract] [Full Text] [PDF]

				D. C. Danila, X. Zhang, Y. Zhou, J. N. S. Haidar, and A. Klibanski Overexpression of Wild-Type Activin Receptor Alk4-1 Restores Activin Antiproliferative Effects in Human Pituitary Tumor Cells J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4741 - 4746. [Abstract] [Full Text] [PDF]

				T. Vanttinen, T. Kuulasmaa, J. Liu, and R. Voutilainen Expression of Activin/Inhibin Receptor and Binding Protein Genes and Regulation of Activin/Inhibin Peptide Secretion in Human Adrenocortical Cells J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4257 - 4263. [Abstract] [Full Text] [PDF]

				J. M. Kuhn, H. Lefebvre, C. Duparc, A. Pellerin, J. P. Luton, and G. Strauch Cosecretion of Estrogen and Inhibin B by a Feminizing Adrenocortical Adenoma: Impact on Gonadotropin Secretion J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2367 - 2375. [Abstract] [Full Text] [PDF]